Expert Opinion on Emerging Drugs最新文献

筛选
英文 中文
PROTAC degraders for lymphoid malignancies - current status and future directions. 淋巴恶性肿瘤PROTAC降解剂的现状和未来发展方向。
IF 3.8 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2026-11-01 DOI: 10.1080/14728214.2026.2755072
Anna Wolska-Washer, Tadeusz Robak
{"title":"PROTAC degraders for lymphoid malignancies - current status and future directions.","authors":"Anna Wolska-Washer, Tadeusz Robak","doi":"10.1080/14728214.2026.2755072","DOIUrl":"10.1080/14728214.2026.2755072","url":null,"abstract":"<p><strong>Introduction: </strong>Despite remarkable advances in targeted therapy, some patients with lymphoid malignancies develop resistance to all available treatment modalities. Proteolysis-targeting chimeras (PROTACs), harness the ubiquitin-proteasome system to eliminate both catalytic and scaffolding protein functions of disease-causing proteins, offering a strategy to overcome this resistance.</p><p><strong>Areas covered: </strong>This review discusses the mechanisms of PROTAC activity, current preclinical and clinical data across lymphoid malignancies, and challenges for this emerging therapeutic class. PubMed, Google Scholar, and major hematology conference proceedings (ASH, ASCO, EHA) from 2017 to April 2026 were reviewed. Search terms included combinations of: PROTAC, targeted protein degradation, cereblon, von Hippel-Lindau, combined with individual disease terms and target names.</p><p><strong>Expert opinion: </strong>Among PROTACs, BTK degraders, tacabrutideg (BGB-16673) and bexobrutideg (NX-5948), have demonstrated overall response rates exceeding 75% in heavily pretreated relapsed/refractory CLL/SLL. The STAT3 degrader KT-333 and the IKZF1/3 degrader cemsidomide (the so-called molecular glue) have shown proof-of-concept clinical activity in T-cell and Hodgkin lymphomas. The durability of responses, long-term safety and predictive biomarkers have yet to be defined. The ongoing phase III trial of tacabrutideg will likely determine whether PROTACs become an established treatment option in lymphoid malignancies.</p>","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-11"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nucleic acid-based and small-molecule therapies for lipoprotein(a) lowering: what the trials teach us and what they do not. 降低脂蛋白(a)的核酸和小分子疗法:试验教给我们什么,没有教给我们什么。
IF 3.8 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2026-11-01 DOI: 10.1080/14728214.2026.2755069
Takayuki Yamaji, Fotios Barkas, Kausik K Ray
{"title":"Nucleic acid-based and small-molecule therapies for lipoprotein(a) lowering: what the trials teach us and what they do not.","authors":"Takayuki Yamaji, Fotios Barkas, Kausik K Ray","doi":"10.1080/14728214.2026.2755069","DOIUrl":"https://doi.org/10.1080/14728214.2026.2755069","url":null,"abstract":"","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-6"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging therapies for pericarditis: from anti-IL-1 agents to novel therapeutic options. 心包炎的新疗法:从抗il -1药物到新的治疗选择。
IF 3.8 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2026-10-03 DOI: 10.1080/14728214.2026.2726141
Massimo Imazio, Valentino Collini, Francesco Venturelli, Maria Cristina Tomat, Giulio Savonitto, Davide Stolfo
{"title":"Emerging therapies for pericarditis: from anti-IL-1 agents to novel therapeutic options.","authors":"Massimo Imazio, Valentino Collini, Francesco Venturelli, Maria Cristina Tomat, Giulio Savonitto, Davide Stolfo","doi":"10.1080/14728214.2026.2726141","DOIUrl":"10.1080/14728214.2026.2726141","url":null,"abstract":"<p><strong>Introduction: </strong>Although often self-limited, acute pericarditis recurs in up to 30% of patients. Recurrent pericarditis (RP) causes substantial morbidity (pain, fatigue, and impaired quality of life) and can lead to constriction. Traditional treatments have important limitations, including corticosteroid dependence, recurrent flares, and treatment-related adverse effects. Emerging targeted immunomodulators are therefore under active investigation.</p><p><strong>Areas covered: </strong>This review summarizes the burden of pericarditis across etiologies, current therapies, and the global market for pericarditis treatment. We then focus on novel agents in development with an emphasis on phase II/III studies. The pathobiology of pericardial inflammation (notably interleukin (IL)-1 and inflammasome pathways) is discussed as the rationale for targeted drugs. We review key trials of IL-1 inhibitors, NLRP3 inhibitors (VTX2735), and other innovations (e.g. cannabidiol-based CardiolRx). Potential obstacles to development are examined.</p><p><strong>Expert opinion: </strong>Randomized-withdrawal trials support a marked reduction in recurrences with IL-1 blockade in selected patients with inflammatory, colchicine-resistant and corticosteroid-dependent RP. However, open-label enrichment, small samples, short follow-up, uncertain durability after withdrawal, cost, and limited evidence outside idiopathic or post-cardiac injury disease restrict generalizability. New pipeline agents hold promise for broader use, however, remain investigational until controlled trials establish their efficacy and long-term safety.</p>","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-8"},"PeriodicalIF":3.8,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging drugs for diabetic macular edema: an update. 治疗糖尿病黄斑水肿的新药物:最新进展。
IF 3.8 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2026-10-01 DOI: 10.1080/14728214.2026.2739626
Charles Zhang, Sinan Ersan, Abdullah Virk, Alexander E Higgins, Ingrid U Scott, Harry W Flynn
{"title":"Emerging drugs for diabetic macular edema: an update.","authors":"Charles Zhang, Sinan Ersan, Abdullah Virk, Alexander E Higgins, Ingrid U Scott, Harry W Flynn","doi":"10.1080/14728214.2026.2739626","DOIUrl":"https://doi.org/10.1080/14728214.2026.2739626","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetic macular edema (DME) is a major cause of vision loss among working‑age adults in the United States. Currently, intravitreal anti-vascular endothelial growth factor (anti‑VEGF) injections are the first‑line pharmacological treatment for the management of center‑involving DME. However, real‑world outcomes with anti-VEGF injections are suboptimal due to limited durability, inconsistent follow‑up, and incomplete response.</p><p><strong>Areas covered: </strong>Novel therapeutic approaches include multi-target biologics combining VEGF inhibition with complementary pathways, non-VEGF barrier-restorative biologics, inflammation-modulating agents, small-molecule VEGF-pathway tyrosine kinase inhibitors, alternative corticosteroid delivery approaches, and ocular gene-therapy vectors.</p><p><strong>Expert opinion: </strong>Emerging therapies are likely to complement rather than immediately replace the current anti-VEGF paradigm. Durable therapies including sustained-release implants and gene therapy demonstrate promise in reducing treatment burden and integrate well into the current treatment paradigm. Combination strategies targeting VEGF alongside complementary inflammatory or vascular pathways may improve outcomes in patients with incomplete response, although prospective studies are still needed to identify the patients most likely to benefit from these approaches. Agents seeking to replace the current anti-VEGF regimens face the greatest challenges. Ultimately, the clinical adoption of these therapies will depend on demonstrating durable efficacy, an acceptable safety profile, procedural feasibility, and payer acceptance.</p>","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-17"},"PeriodicalIF":3.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging drugs for the treatment of gastrointestinal stromal tumors: a spotlight on bezuclastinib and the evolving treatment landscape. 用于治疗胃肠道间质瘤的新兴药物:聚焦于贝zuclastinib和不断发展的治疗前景。
IF 3.8 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2026-09-30 DOI: 10.1080/14728214.2026.2739621
Javier Pozas, Andrea Napolitano, Robin L Jones
{"title":"Emerging drugs for the treatment of gastrointestinal stromal tumors: a spotlight on bezuclastinib and the evolving treatment landscape.","authors":"Javier Pozas, Andrea Napolitano, Robin L Jones","doi":"10.1080/14728214.2026.2739621","DOIUrl":"10.1080/14728214.2026.2739621","url":null,"abstract":"","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-5"},"PeriodicalIF":3.8,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149037348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted oral peptide therapy for inflammatory bowel disease: focus on the IL-23 receptor antagonist icotrokinra. 靶向口服肽治疗炎症性肠病:重点研究IL-23受体拮抗剂icotrokinra。
IF 3.8 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2026-09-28 DOI: 10.1080/14728214.2026.2739622
Daniele Noviello, Flavio Caprioli, Nurulamin M Noor
{"title":"Targeted oral peptide therapy for inflammatory bowel disease: focus on the IL-23 receptor antagonist icotrokinra.","authors":"Daniele Noviello, Flavio Caprioli, Nurulamin M Noor","doi":"10.1080/14728214.2026.2739622","DOIUrl":"10.1080/14728214.2026.2739622","url":null,"abstract":"","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-4"},"PeriodicalIF":3.8,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances in hidradenitis suppurativa therapeutics: a focus on existing and future medical therapeutics. 化脓性汗腺炎治疗的最新进展:对现有和未来医学治疗方法的关注。
IF 3.8 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2026-09-09 DOI: 10.1080/14728214.2026.2731005
Camila R Marquez, Aditya Joshi, Lauren Gawey, Stacey N Giuffre, Crystal Khem, Jennifer L Hsiao, Vivian Y Shi
{"title":"Recent advances in hidradenitis suppurativa therapeutics: a focus on existing and future medical therapeutics.","authors":"Camila R Marquez, Aditya Joshi, Lauren Gawey, Stacey N Giuffre, Crystal Khem, Jennifer L Hsiao, Vivian Y Shi","doi":"10.1080/14728214.2026.2731005","DOIUrl":"10.1080/14728214.2026.2731005","url":null,"abstract":"<p><strong>Introduction: </strong>HS is an inflammatory skin condition that causes abscesses, nodules, and tunnels in intertriginous areas. Treatment consists of multimodal therapy such as topical and systemic antibiotics, washes and ointments, hormonal modulation, retinoids, surgery, and recently biologic therapy. The FDA approved three biologics for HS in the last 10 years, although novel options are needed for recalcitrant disease.</p><p><strong>Areas covered: </strong>A comprehensive search of the National Institutes of Health (NIH) Clinical Trials database was performed in April 2025, with an updated search in October 2025. Trials were limited to hidradenitis suppurativa, phase II or III, and a status of not yet recruiting, recruiting, active, completed, or terminated. Data were supplemented with a PubMed query and an internet search for data and press releases from companies. Results include 52 phase 2 and 16 phase 3 studies.</p><p><strong>Expert opinion: </strong>Biologics serve as a steppingstone to a new age of therapy for HS. Investigations are needed for recalcitrant disease, to minimize adverse events, and provide personalized treatment. Compounds with promise include JAK inhibitors, while other compounds await results, and others limited by small sample sizes and non-randomized study designs. Future trials should focus on comparative drug designs and ensuring fair access for all, particularly patients with the highest disease burden.</p>","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-19"},"PeriodicalIF":3.8,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148896941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute management of adult MOG antibody-associated disease: therapeutic choices and clinical outcomes. MOGAD的急性管理:治疗选择和临床结果。
IF 3.8 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2026-09-01 Epub Date: 2026-06-18 DOI: 10.1080/14728214.2026.2689745
Edgar Carnero Contentti, Eoin P Flanagan, Ethel Ciampi
{"title":"Acute management of adult MOG antibody-associated disease: therapeutic choices and clinical outcomes.","authors":"Edgar Carnero Contentti, Eoin P Flanagan, Ethel Ciampi","doi":"10.1080/14728214.2026.2689745","DOIUrl":"10.1080/14728214.2026.2689745","url":null,"abstract":"","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"67-71"},"PeriodicalIF":3.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
σ1 receptor agonists: the new trend or an emerging therapeutic option? 西格玛1受体激动剂:新趋势还是新治疗选择?
IF 3.8 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2026-09-01 Epub Date: 2026-07-02 DOI: 10.1080/14728214.2026.2696872
Tangui Maurice
{"title":"σ<sub>1</sub> receptor agonists: the new trend or an emerging therapeutic option?","authors":"Tangui Maurice","doi":"10.1080/14728214.2026.2696872","DOIUrl":"10.1080/14728214.2026.2696872","url":null,"abstract":"","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"79-82"},"PeriodicalIF":3.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148344329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging claudin-18.2 antagonists in the treatment of biliary tract cancer. 新出现的claudin-18.2拮抗剂治疗胆道癌。
IF 3.8 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2026-09-01 Epub Date: 2026-06-05 DOI: 10.1080/14728214.2026.2681745
Daniel Neureiter, Dino Bekric, Christian Mayr, Tobias Kiesslich, Matthias Ocker
{"title":"Emerging claudin-18.2 antagonists in the treatment of biliary tract cancer.","authors":"Daniel Neureiter, Dino Bekric, Christian Mayr, Tobias Kiesslich, Matthias Ocker","doi":"10.1080/14728214.2026.2681745","DOIUrl":"10.1080/14728214.2026.2681745","url":null,"abstract":"<p><strong>Introduction: </strong>The tight junction protein Claudin-18.2 (CLDN-18.2) has been identified as a novel drug target for various solid tumors, including biliary tract cancers (BTC). Antibody-based approaches to target CLDN-18.2 have shown promising results in early clinical trials and several novel modalities like antibody-drug conjugates, bispecific T-cell engagers or CAR T-cells are currently also explored.</p><p><strong>Areas covered: </strong>This review discusses the translational knowledge and gaps related to the underrepresentation of BTC in early clinical (basket) studies. We outline the current status of early clinical trials of drugs targeting CLDN-18.2 in BTC and discuss the need to determine prevalence and cutoff data in larger cohorts to overcome limitations related to clinical and molecular heterogeneity of BTC.</p><p><strong>Expert opinion: </strong>Targeting CLDN-18.2 is a promising novel approach to treat solid tumors, including BTC. To confirm encouraging first clinical data, larger studies specific for BTC are needed to address tumor heterogeneity and to determine cutoff levels of CLDN-18.2 expression. Such studies are also needed to understand combination options and sequencing of therapies and to further validate novel approaches to fully exploit the potential of targeting CLDN-18.2 in BTC.</p>","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"83-93"},"PeriodicalIF":3.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书